GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3954
-0.0046 (-1.15%)
As of 12:57PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4000
Open0.4045
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3900 - 0.4050
52 Week Range0.2100 - 1.56
Volume166,605
Avg. Volume566,468
Market Cap71.868M
Beta-1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.1730
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
    PR Newswireyesterday

    GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market

    The first six proprietary strains are being cultivated by The Colorado Hemp Project and will serve as the basis for fresh revenue streams from both retail sales and raw ingredients for cannabis-based medical formulations. LAS VEGAS, July 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) updates the progress in their efforts to identify, cultivate and extract full spectrum hemp oil from proprietary hemp strains that contain desirable ratios of CBD, cannabinoids and terpenes to provide the necessary compounds to support both the Company's medical Intellectual Properties portfolio and open a fresh revenue stream in the rapidly growing retail hemp market. The search for a full spectrum hemp oil product that matched the quality and consistency of their cannabis genetics led GB Sciences to The Colorado Hemp Project.

  • GB Sciences One of Ten Companies Named in Important New Canadian Research Publication
    PR Newswire8 days ago

    GB Sciences One of Ten Companies Named in Important New Canadian Research Publication

    LAS VEGAS, July 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) was named as one of the ten select cannabis companies in North America according to a study conducted by a leading investment banking firm in their June 20, 2018 Industry Report on Medical Cannabis. GB Sciences was the only U.S. publicly traded company to make the list of ten companies.

  • GlobeNewswire20 days ago

    GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain

    GB Sciences, Inc. (GBLX) has filed a new provisional patent application on the use of cannabis-based therapies for the manipulation of cannabis-sensitive ion channels in sensory neurons that contribute to chronic inflammatory pain conditions, peripheral neuropathy, urinary cystitis, asthma, and specific types of hearing loss. The GB Sciences drug development team believes that these new cannabis-based treatments could well herald the dawning of ‘individualized medicines’ from the cannabis plant by re-establishing balance in each individual patient’s endocannabinoid system. “Manipulating the TRP channels in sensory neurons could provide much needed relief for patients who are suffering from chronic pain, asthma, urinary cystitis, or hearing loss,” explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences.

  • GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain
    PR Newswire22 days ago

    GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain

    The nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures. LAS VEGAS , June 25, 2018 /PRNewswire/ -- GB Sciences, Inc. ...

  • GlobeNewswire2 months ago

    GB Sciences Puts Its Grey Matter To Work Solving The Big Green Riddle...

    For large scale adoption of Cannabis in medical formulations the quality, consistency and trust in the raw ingredients is essential in providing a true scientific base line and prove efficacy in the medical world. “This technique allows us to produce healthy, genetically identical copies of prime mother plants resulting in optimal cannabinoid and terpene profiles over multiple grow cycles.

  • PR Newswire2 months ago

    GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments Covered By Medical Cannabis Legislation

    LAS VEGAS, May 22, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), it all started with one woman's plea and ended with a call to action for a dramatic expansion of diseases treated by medical cannabis throughout the State of Louisiana. The passage of the Alison Neustrom Act in 2015 opened the door for a relatively small number of qualified patients to legally receive medical marijuana treatment. The passage of two new House Bills increases the patient count to include patients with additional qualifying disease conditions in the State.

  • GB Sciences' Acquisition Of NevadaPURE Is Terminated
    PR Newswire2 months ago

    GB Sciences' Acquisition Of NevadaPURE Is Terminated

    LAS VEGAS, May 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), the previously announced proposed acquisition of NevadaPURE, LLC, a Nevada limited liability company, by GB Sciences has been terminated. In accordance with the terms of the non-binding letter of intent signed between the parties and after the due diligence period (which was mutually extended by one week), GB Sciences and NevadaPURE, LLC mutually agreed not to proceed with the transaction. GB Sciences' Chairman of the Board and CEO John Poss said: "A nondisclosure agreement between the parties prevents GB Sciences from making extensive comments on the proposed transaction.

  • ACCESSWIRE2 months ago

    Marijuana Stocks for Investors in the Free Cannabis Investor Magazine

    MIAMI, FL / ACCESSWIRE / May 7, 2018 / Cannabis Investor Magazine , the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced ...

  • ACCESSWIRE2 months ago

    GB Sciences is Exploring a Cannabis Therapy for Parkinson's, Analysts Review

    The company recently announced that it is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease. The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. Furthermore, the transaction also enables GB Sciences with access to three licenses from the state of Nevada for cultivation and production of marijuana along with the one for running a dispensary.

  • ACCESSWIRE3 months ago

    GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018

    DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...

  • GlobeNewswire3 months ago

    GB Sciences, CEO, John Poss, Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast

    PHOENIX, April 19, 2018-- GB Sciences, Inc., today announced CEO, John Poss, returned to Uptick Newswire’ s“ Stock Day” podcast with Everett Jolly for an operational update.. “GB Sciences is a cannabis ...

  • PR Newswire3 months ago

    Exploratory IND Is Planned Using GB Sciences' Proprietary Mixtures of Botanical Compounds to Provide the Highest Efficacy for Patients

    LAS VEGAS, April 17, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), as previously reported, plans to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data, to support clinical development decisions on prioritizing among multiple, related Parkinson's Disease ("PD") formulations.  GB Sciences has a patent application covering multiple, related PD-formulas that are based on complex mixtures of minor cannabinoids and terpenes from cannabis chemovars. In preclinical studies, GB Sciences has demonstrated that complex mixtures of cannabis-based compounds may provide greater clinical benefits than single compound treatments due to molecular synergies for the treatment of Parkinson's.

  • GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease
    PR Newswire3 months ago

    GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease

    LAS VEGAS, April 10, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD").  The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. An Exploratory IND requires less pre-clinical data and offers a more flexible way to get essential information about potential drug development candidates than a more conventional early phase development program. Performing an FDA-Registered clinical trial, instead of a Nevada-based pilot trial as reported earlier, also translates to quicker entry into international markets with harmonized regulatory standards.

  • GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula
    PR Newswire3 months ago

    GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula

    LAS VEGAS, April 4, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has completed the technology transfer for the manufacturing of time-released nanoparticles containing a cannabinoid-based therapeutic for neuropathic pain from the University of Seville. As announced in Q4 of 2017, GB Sciences has obtained the exclusive worldwide license to the intellectual property covering this time-released cannabinoid formulation from the University of Seville ("USE"), the Centro de Investigación Biomédica en Red de Salud Mental ("CIBERSAM") and the University of Cadiz ("UCA").

  • GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
    PR Newswire4 months ago

    GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues

    LAS VEGAS, March 28, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE's Las Vegas operation for $28 million in cash and the assumption of approximately $5 million of outstanding liabilities. The annualized sales run rate of NevadaPURE is over $16 million based on its performance since adult use became legal in Nevada, making the purchase price only two times sales.  This sales multiple compares with GB's current price-to-annualized-sales multiple of 16, and a typical multiple of 60 or much more for publicly traded cannabis companies whose sales are similar to GB's.

  • GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
    CNW Group4 months ago

    GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues

    GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues

  • PR Newswire4 months ago

    Research Projects Sales of Legal Cannabis Products to Accelerate This Year

    According to a report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is estimated to grow at a CAGR of 21.1% between 2017 to 2024, while reaching a value of $63.5 billion by 2024. The market is going through a period of robust growth because of increasing legalization and decriminalization of cannabis products across North America. Data by Arcview Market Research clarifies that growth of the legal cannabis industry are expected reaccelerate in 2018, as adult use sales ramp up in Canada, California, and Massachusetts along with medical sales in Florida.

  • GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium
    PR Newswire4 months ago

    GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium

    LAS VEGAS, March 15, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce their sponsorship of the 1st Annual "Innovation in Medical Cannabis Therapies" Symposium in Las Vegas, Nevada, on Friday, June 1st, 2018.  Top innovators in cannabis tech, biotech, nanotech, and metabolomics are invited to this collaborative discussion, which was designed to explore the necessary advances across multiple fields that are required for the development of safe and effective plant-based medicines. The GBS approach to research is always grounded in solid science and The Life Sciences team, a division of GB Sciences, has discovered that other researches who ascribe to this nontraditional mindset usually find funding and partnering difficult to come by.

  • GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium
    CNW Group4 months ago

    GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium

    GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium

  • GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project
    CNW Group5 months ago

    GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project

    GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project

  • GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project
    PR Newswire5 months ago

    GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project

    LAS VEGAS, Feb. 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations. The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and companies everywhere. GB Sciences believes that hemp will provide an important palette upon which important compounds can be created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial cannabinoids.

  • GB Sciences Receives Issuance of Its Cannabis Oil Production License
    PR Newswire5 months ago

    GB Sciences Receives Issuance of Its Cannabis Oil Production License

    LAS VEGAS, Feb. 21, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has been issued its production license and now begins full production operations in the Las Vegas, Nevada facility. Production license partners include Relax With Happy™ ("RWH"), a new venture co-founded by veteran cannabis chef, Deliciously Dee™, and Cura Cannabis Solutions, maker of the best-selling cannabis brand on the West Coast, Select Oil.

  • GB Sciences Receives Issuance of Its Cannabis Oil Production License
    CNW Group5 months ago

    GB Sciences Receives Issuance of Its Cannabis Oil Production License

    GB Sciences Receives Issuance of Its Cannabis Oil Production License

  • PR Newswire5 months ago

    GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana

    LAS VEGAS, Feb. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and its wholly-owned subsidiary GB Sciences Louisiana, LLC. (GBSL) are pleased to announce the completion of a new agreement with Wellcana Group, LLC. (Wellcana) to work together on the previously announced initiative for the development of medical cannabis in Louisiana, a joint effort of the Louisiana State University AgCenter and GBSL, operating under the AgCenter's medical cannabis license, which is one of only two licenses granted by the State. The terms of the agreement provide that Wellcana will buy 15% of the newly-issued equity of GBSL for $3 million.  Wellcana also has an option to purchase an additional 35% for an additional $7 million investment.

  • CNW Group5 months ago

    GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana

    GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana